07.01.2013 - Vivus said prescriptions for obesity drug Qsymia, its main product, rose nearly 68% in the month ended Dec. 21 compared with the preceding four weeks, well above industry forecasts...
Advertising Opportunities Print, Digital & Content Solutions
LinkedIn | X (Twitter)